Vivos Inc. Advances RadioGel® Trials, Paving Future for Cancer Care

Vivos Inc. Expands its RadioGel® Clinical Trials in India

Today, Vivos Inc. (OTCQB: RDGL) is thrilled to announce significant advancements in their clinical trials for RadioGel® Precision Radionuclide Therapy™, a groundbreaking treatment for solid tumors. This therapy has garnered recognition as a Breakthrough Device from the FDA, reflecting its immense potential in oncology.

Clinical Trial Progress and Outcomes

In our latest update, we share that, building on the initial successes reported earlier this year, we have treated ten patients with cancerous nodes using RadioGel®. The trials have continued to affirm the safety of the therapy, showing no adverse events and excellent patient recovery.

Each patient met the crucial safety endpoint, confirmed through PET imaging, which demonstrated precise retention of the Yttrium-90 isotope. This pinpoint accuracy of the treatment resulted in no damage to surrounding healthy tissues, especially critical for patients with tumors located near vital areas such as the trachea and carotid artery.

Advancements in Technological Techniques

The experience and expertise of the clinical team in India have been instrumental in refining the treatment delivery methods. We have introduced innovative techniques such as deep-needle injection and precision imaging guidance. Additionally, the implementation of saline spacers enhances dose control and maximizes organ protection during the procedure.

Discussions with leading U.S. investigators from Mayo Clinic are progressing, examining the integration of these advancements into a forthcoming parallel study in the United States, aimed at reinforcing the global therapeutic landscape.

Future Directions in Patient Treatment

Our current study in India has received approval to treat a total of 30 patients, with plans to upscale this to 50 patients pending Ethics Committee review. Expanding the trials will allow for a more comprehensive evaluation of RadioGel® across various tumor types, including those that are notoriously challenging to treat, such as lung and pancreatic cancers.

Strengthening Global Presence

In addition to our clinical advancements, Vivos is laying down the framework for sustainable operations in India. We aim to establish a corporate office alongside a manufacturing facility dedicated to yttrium phosphate microparticles. Such an infrastructure will ensure the successful rollout and future commercial availability of RadioGel® in India, marking it as a crucial hub for further global expansion.

Our upcoming submission of clinical data, intended for peer-reviewed publication, is anticipated to significantly bolster awareness among medical professionals, potentially leading to impactful regulatory submissions worldwide.

Strategizing Regulatory Engagement

With the FDA's Breakthrough Device designation of RadioGel®, we are proactively sharing preliminary results from the India trials to facilitate our objective of applying for an Investigational Device Exemption (IDE) within a short timeframe.

While we remain optimistic about our regulatory trajectory, we are cognizant of the unpredictable nature of the U.S. regulatory environment. This awareness drives us to adopt a multi-faceted global strategy, catering not only to U.S. markets but also taking advantage of opportunities in regions with more streamlined regulatory processes.

Market Opportunities and Strategic Vision

The cancer treatment landscape in India is ripe with potential, with a current market valuation of approximately USD 4.21 billion, projected to skyrocket to USD 5.89 billion by the end of the decade. This surge highlights a significant opening for innovative treatments like RadioGel®, providing a compelling opportunity for Vivos to enhance shareholder value through diversification and global recognition.

Dr. Michael Korenko, President and CEO of Vivos Inc., stated, "With each patient treated, RadioGel® reveals its true value. We’re witnessing not only promising outcomes but also reinforcing the confidence in our technology. The FDA's designation of RadioGel® as a Breakthrough Device highlights our commitment to introduce innovative cancer treatment solutions to patients in need." Furthermore, he shared insights about the results emanating from the IsoPet® animal health division, reinforcing the effectiveness of their technologies across both human and veterinary applications.

Frequently Asked Questions

What is RadioGel®?

RadioGel® is a precision radionuclide therapy utilizing Yttrium-90 to deliver targeted radiation directly into tumors, minimizing damage to healthy tissue.

How is the clinical trial in India progressing?

The trial has successfully treated ten patients, showing a strong safety profile and no adverse events this far, which strengthens the foundation for future studies.

What are the next steps for Vivos Inc.?

Vivos plans to expand the clinical trial cohort from 30 to 50 patients and establish operational sites in India to support the treatment rollout.

How does Vivos Inc. view regulatory challenges?

While optimistic about progress, Vivos acknowledges the complexities of the regulatory landscape and is pursuing a diverse strategy to expedite global adoption of RadioGel®.

What industry opportunities does the Indian market present?

The Indian cancer treatment market presents substantial growth potential, with projections indicating significant value increases, indicating a robust opportunity for innovative therapies like RadioGel®.

About The Author

Greetings, I'm 32-year-old author and financial specialist Evelyn Baker. My introduction into the financial industry started with an economics degree and continued with a wealth of experience in wealth management and financial consulting. My great passion over the years has been assisting people and companies in making wise, well-informed decisions to reach their financial objectives.

My goal with writing is to simplify difficult financial ideas into understandable, doable guidance. My goal in writing many books and articles is to make personal finance understandable to everyone, irrespective of their experience or background. I want to give readers the information they need to take charge of their financial futures, from investing and retirement planning to budgeting and saving.

Along with my writing, I lead webinars and workshops where I provide doable advice and methods for achieving financial success. To reach a larger audience, I also frequently contribute to financial blogs and publications. My method is always to offer doable, real-world guidance that can actually improve people's lives.

Aside from my job, I like to cook, travel, and experience other cultures. I work hard to apply my belief in the value of a balanced life to my financial counsel. My goal in working is to encourage and enable people to succeed financially so they may lead the best lives possible.

Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.